A role for the dehydrogenase DHRS7 (SDR34C1) in prostate cancer

Several microarray studies of prostate cancer (PCa) samples have suggested altered expression of the “orphan” enzyme short‐chain dehydrogenase/reductase DHRS7 (retSDR4, SDR34C1). However, the role of DHRS7 in PCa is largely unknown and the impact of DHRS7 modulation on cancer cell properties has not yet been studied. Here, we investigated DHRS7 expression in normal human prostate and PCa tissue samples at different tumor grade using tissue microarray and immunovisualization. Moreover, we characterized the effects of siRNA‐mediated DHRS7 knockdown on the properties of three distinct human prostate cell lines. We found that DHRS7 protein expression decreases alongside tumor grade, as judged by the Gleason level, in PCa tissue samples. The siRNA‐mediated knockdown of DHRS7 expression in the human PCa cell lines LNCaP, BPH1, and PC3 significantly increased cell proliferation in LNCaP cells as well as cell migration in all of the investigated cell lines. Furthermore, cell adhesion was decreased upon DHRS7 knockdown in all three cell lines. To begin to understand the mechanisms underlying the effects of DHRS7 depletion, we performed a microarray study with samples from LNCaP cells treated with DHRS7‐specific siRNA. Several genes involved in cell proliferation and adhesion pathways were found to be altered in DHRS7‐depleted LNCaP cells. Additionally, genes of the BRCA1/2 pathway and the epithelial to mesenchymal transition regulator E‐cadherin were altered following DHRS7 knockdown. Based on these results, further research is needed to evaluate the potential role of DHRS7 as a tumor suppressor and whether its loss‐of‐function promotes PCa progression and metastasis.

[1]  Q. Qu,et al.  The Effects of Lycopene on the Methylation of the GSTP1 Promoter and Global Methylation in Prostatic Cancer Cell Lines PC3 and LNCaP , 2014, International journal of endocrinology.

[2]  J. Korbel,et al.  Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer , 2014, International journal of cancer.

[3]  Michael V. Fiandalo,et al.  Roles for the Backdoor Pathway of Androgen Metabolism in Prostate Cancer Response to Castration and Drug Treatment , 2014, International journal of biological sciences.

[4]  E. Antonarakis,et al.  Castration-resistant prostate cancer: latest evidence and therapeutic implications , 2014, Therapeutic advances in medical oncology.

[5]  J. Dunford,et al.  Biochemical properties of human dehydrogenase/reductase (SDR family) member 7. , 2014, Chemico-biological interactions.

[6]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[7]  N. Kyprianou,et al.  Androgen regulation of epithelial–mesenchymal transition in prostate tumorigenesis , 2011, Expert review of endocrinology & metabolism.

[8]  M. Negri,et al.  17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: Protein structures, functions, and recent progress in inhibitor development , 2011, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  Allen D. Delaney,et al.  LNCaP Atlas: Gene expression associated with in vivo progression to castration-recurrent prostate cancer , 2010, BMC Medical Genomics.

[10]  Liang Cheng,et al.  Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. , 2010, Human pathology.

[11]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[12]  Manoj Bhasin,et al.  Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer , 2009, Clinical Cancer Research.

[13]  Janet M Thornton,et al.  The SDR (short-chain dehydrogenase/reductase and related enzymes) nomenclature initiative. , 2009, Chemico-biological interactions.

[14]  H. Tutill,et al.  Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. , 2008, Endocrine-related cancer.

[15]  Loredana Moro,et al.  Loss of BRCA2 promotes prostate cancer cell invasion through up‐regulation of matrix metalloproteinase‐9 , 2008, Cancer science.

[16]  D. Grignon,et al.  Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. , 2007, International journal of radiation oncology, biology, physics.

[17]  R. Hynes,et al.  Protein 4.1B suppresses prostate cancer progression and metastasis , 2007, Proceedings of the National Academy of Sciences.

[18]  R. Abaza,et al.  Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy. , 2006, The Journal of urology.

[19]  J. Adamski,et al.  Bioinformatic identification and characterization of new members of short-chain dehydrogenase/reductase superfamily , 2006, Molecular and Cellular Endocrinology.

[20]  M. Sadar,et al.  Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. , 2005, The Journal of urology.

[21]  M. Hewison,et al.  11β-Hydroxysteroid dehydrogenases, cell proliferation and malignancy , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[22]  L. Bubendorf,et al.  Tissue microarray analysis reveals prognostic significance of syndecan‐1 expression in prostate cancer , 2003, The Prostate.

[23]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[24]  G. Christofori,et al.  The tumor-suppressor function of E-cadherin. , 1998, American journal of human genetics.

[25]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[26]  M. Erdos,et al.  BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins , 1998, Oncogene.

[27]  D. Allred,et al.  Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[28]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[29]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[30]  R. Dahiya,et al.  Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1 , 2007, In Vitro Cellular & Developmental Biology - Animal.

[31]  John T. Wei,et al.  Integrative molecular concept modeling of prostate cancer progression , 2007, Nature Genetics.

[32]  K. Palczewski,et al.  Short-chain dehydrogenases/reductases in retina. , 2000, Methods in enzymology.

[33]  R. Kath,et al.  [Tumor progression and metastasis]. , 1990, Zentralblatt fur Chirurgie.